Figyelem helyszín változás!!

Új helyszín: Budapest, Kongresszusi Központ

Distinguished Colleagues, dear Friends, 

On behalf of the Hungarian Society of Cardiology’s Working Group on Cardiac Arrhythmias and Pacing (WGCAP of HSC), we would like to welcome you to the second Budapest International Arrhythmia Symposium (BIAS-2). We are honoured that this two-days in english and 1 day in hungarian scientific symposium is held this time in our amazing capital, Budapest, between 19–21 September 2024. 

Akkreditáció 

A tanfolyam a Semmelweis Egyetem által SE-SZTOK/2024.II/00118 kódszámon – tesztvizsga esetén - 48 kreditpontra akkreditált. Az alábbi szakképesítés(ek) birtokában a megszerzett pontszám „SZAKMA SZERINTI” tanfolyamon megszerzettnek minősül. Egészségügyi szakdolgozók 20 pontot szerezhetnek.
 
REGISZTRÁCIÓ
 
További információk és a preogram letölthető a rendezvény oldalán: convention.hu

Why join?
New data from cardiovascular outcomes trials in diabetes have shown that some newer agents have proven CV benefits (e.g. GLP-1 receptor agonists and SGLT2 inhibitors). The compelling evidence has led to significant changes in treatment paradigms as reflected by the new ADA/EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes.

This highly interactive and skills-based Masterclass will provide an opportunity to discuss the rationale and benefits of new clinical approaches and to share experiences with experts in the field of diabetes management.

Sessions will include:
• Strategies for individualizing therapy
• Applying new diabetes therapies with CV benefit in practice 
• Assessing cardiovascular risk 
• Obesity as a treatable condition 
• Instilling confidence in patients in using injectables 
• New formulations on the horizon

How do I join?
The masterclass is free of charge, travel and accommodation will be provided as appropriate.

To submit an application please visit https://integress.cvent.com/ASCENDMasterclass Places are limited.

Invitation

Why join?
New data from cardiovascular outcomes trials in diabetes have shown that some newer agents have proven CV benefits (e.g. GLP-1 receptor agonists and SGLT2 inhibitors). The compelling evidence has led to significant changes in treatment paradigms as reflected by the new ADA/EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes.

This highly interactive and skills-based Masterclass will provide an opportunity to discuss the rationale and benefits of new clinical approaches and to share experiences with experts in the field of diabetes management.

Sessions will include:
• Strategies for individualizing therapy
• Applying new diabetes therapies with CV benefit in practice 
• Assessing cardiovascular risk 
• Obesity as a treatable condition 
• Instilling confidence in patients in using injectables 
• New formulations on the horizon

How do I join?
The masterclass is free of charge, travel and accommodation will be provided as appropriate.

To submit an application please visit https://integress.cvent.com/ASCENDMasterclass Places are limited.

Invitation